IP Library Granted Patent US 10,899,761
Granted Patent B2
US 10,899,761 · App. 16/838,383 · Granted Jan 26, 2021

Heterocyclic compounds and uses thereof

Inventors: Prabha N. Ibrahim (Mountain View, CA); Wayne Spevak (Berkeley, CA); Jiazhong Zhang (Foster City, CA); Songyuan Shi (Fremont, CA); Ben Powell (Pleasant Hill, CA); Yan Ma (Belmont, CA)
Assignee: Plexxikon Inc.
C07D471/04A61K31/444A61K31/5377
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,899,761
App. No.
16/838,383
Granted
Jan 26, 2021
Kind
B2
Abstract

Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Claims (10)

1. A method for treating an inflammatory response to a viral infection comprising administering to a subject in need thereof an effective amount of a compound of formula (II):

or a pharmaceutically acceptable salt thereof, wherein R 1 is (C 1 -C 3 )alkyl.

2. A method for treating an inflammatory response to a viral infection comprising administering to a subject in need thereof an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the inflammatory response is to a coronavirus infection.

4. The method of claim 2 , wherein the inflammatory response is to a coronavirus infection.

5. A method for treating synovial sarcoma comprising administering to a subject in need thereof an effective amount of a compound of formula (II):

or a pharmaceutically acceptable salt thereof, wherein R 1 is (C 1 -C 3 )alkyl.

6. A method for treating synovial sarcoma comprising administering to a subject in need thereof an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE 16TH PATENT NUMBER PREVIOUSLY RECORDED AT REEL: 062856 FRAME: 0846. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Mar 28, 2023
From: OPNA IMMUNO-ONCOLOGY SA
To: OPNA BIO SA
Reel/Frame 063588/0355 →
CHANGE OF NAME Recorded Mar 2, 2023
From: OPNA IMMUNO-ONCOLOGY SA
To: OPNA BIO SA
Reel/Frame 062856/0846 →
CORRECTION OF AN ERROR IN ASSIGNOR'S NAME IN A COVER SHEET PREVIOUSLY RECORDED AT REEL 059925 FRAME 0772. Recorded May 20, 2022
From: PLEXXIKON INC.
To: OPNA IMMUNO-ONCOLOGY SA
Reel/Frame 060131/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: PLEXXICON INC.
To: OPNA IMMUNO-ONCOLOGY SA
Reel/Frame 059925/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2020
From: IBRAHIM, PRABHA N.; SPEVAK, WAYNE; ZHANG, JIAZHONG; SHI, SONGYUAN; POWELL, BEN; MA, YAN
To: PLEXXIKON INC.
Reel/Frame 053040/0891 →
Continuity (6)
Continuation 16441610 · Jun 14, 2019
Continuation 15977772 · May 11, 2018
Continuation 15689931 · Aug 29, 2017
Continuation 15269054 · Sep 19, 2016
Provisional Application 62221508 · Sep 21, 2015
Related Publication 20200339571A1 · Oct 29, 2020
Cited By (1)
US 12,509,444